Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTK | P29376 | 2/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | MARK3 | P27448 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.55 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.55 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.55 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815006 | 0.89 | LTK (0.59) | LTKAURKBCHEK2ROS1MARK3 | |
| SCHEMBL4809739 | 0.84 | LMNA (0.48) | LTKAURKBCHEK2ROS1MARK3 | |
| SCHEMBL4811188 | 0.81 | LTK (0.60) | LTKAURKBCHEK2ROS1MARK3 | |
| SCHEMBL7981630 | 0.75 | MAPT (0.75) | CHEK1CYP3A4MAPTPDGFRBCA1 | |
| SCHEMBL4815206 | 0.71 | LTK (1.00) | LTKAURKBCHEK2ROS1MARK3 | |
| SCHEMBL4854096 | 0.70 | LTK (0.55) | LTKAURKBCHEK2ROS1MARK3 | |
| SCHEMBL4815668 | 0.70 | PDGFRB (0.61) | CHEK1PDGFRB | |
| SCHEMBL31369146 | 0.69 | CYP3A4 (0.62) | CYP3A4MAPTCA1CA2 | |
| SCHEMBL4571013 | 0.69 | CYP3A4 (1.00) | CYP3A4MAPT | |
| SCHEMBL2138785 | 0.69 | CYP3A4 (1.00) | CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | LTK 265/4885AURKB 204/4885CHEK2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.